NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced it has licensed Merck's breast cancer biomarker patent portfolio.

The license allows HTG to develop, manufacture, and commercialize tests based on the portfolio, which is co-owned by the Netherlands Cancer Institute. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.